Series B · Biotech · Copenhagen, Denmark · Founded 2014 · 70–85 employees
IO Biotech is a clinical-stage biopharmaceutical company pioneering first-in-class dual-action immune-modulating cancer vaccines based on their proprietary T-win platform. The company's lead candidate IO102-IO103 (Cylembio) is currently in Phase 3 clinical trials for melanoma and has received FDA Breakthrough Therapy Designation. Their innovative approach targets both tumor cells and immune-suppressive cells in the tumor microenvironment simultaneously. The company has raised $175 million across multiple funding rounds and recently secured up to €57.5 million in debt financing from the European Investment Bank.
No open roles listed right now.